A Mediterranean diet lowers the risk of cancer as does the stopping of smoking. There is tentative evidence that treating H. pylori decreases the future risk. If cancer is treated early, many cases can be cured. Treatments may include some combination of: surgery, chemotherapy, radiation therapy and targeted therapy. If treated late, palliative care may be advised. Outcomes are often poor with a less than 10% 5-year survival rate globally. This is largely because most people with the condition present with advanced disease. In the United States 5-year survival is 28% while in South Korea it is over 65% partly due to screening efforts.
Globally stomach cancer is the fifth leading cause of cancer and the third leading cause of death from cancer making up 7% of cases and 9% of deaths. In 2012 it occurred in 950,000 people and caused 723,000 deaths. Before the 1930s in much of the world, including the United States and the United Kingdom, it was the most common cause of death from cancer. Rates of death have been decreasing in many areas of the world since then. This is believed to be due to the eating of less salted and pickled foods as a result of the development of refrigeration as a method of keeping food fresh. Stomach cancer occurs most commonly in East Asia and Eastern Europe and it occurs twice as often in males as in females.
Endoscopic image of linitis plastica, a type of stomach cancer where the entire stomach is invaded, leading to a leather bottle-like appearance with blood coming out of it.
Endoscopic images of the stomach cancer in early stage. Its histology was poorly differentiated adenocarcinoma with signet ring cells.Left above=Normal, right above=FICE, left low=acetate stained, right low= AIM stained
Stomach cancer is often either asymptomatic (producing no noticeable symptoms) or it may cause only nonspecific symptoms (symptoms that are specific not only to stomach cancer, but also to other related or unrelated disorders) in its early stages. By the time symptoms occur, the cancer has often reached an advanced stage (see below) and may have also metastasized (spread to other, perhaps distant, parts of the body), which is one of the main reasons for its relatively poor prognosis. Stomach cancer can cause the following signs and symptoms:
Gastric cancer is a multifactorial disease.Helicobacter pylori infection is an essential risk factor in 65–80% of gastric cancers, but in only 2% of such infections. The mechanism by which H. pylori induces stomach cancer potentially involves chronic inflammation, or the action of H. pylori virulence factors such as CagA.
Smoking increases the risk of developing gastric cancer significantly, from 40% increased risk for current smokers to 82% increase for heavy smokers. Gastric cancers due to smoking mostly occur in the upper part of the stomach near the esophagus. Some studies show increased risk with alcohol consumption as well.
Dietary factors are not proven causes, but some foods including smoked foods, salt and salt-rich foods, red meat, processed meat, pickled vegetables, and bracken are associated with a higher risk of stomach cancer. Nitrates and nitrites in cured meats can be converted by certain bacteria, including H. pylori, into compounds that have been found to cause stomach cancer in animals. On the other hand, fresh fruit and vegetable intake, citrus fruit intake, and antioxidant intake are associated with a lower risk of stomach cancer. A Mediterranean diet is also associated with lower rates of stomach cancer, as is regular aspirin use.
Sequence of 123-iodine human scintiscans after an intravenous injection, (from left) after 30 minutes, 20 hours and 48 hours. A high and rapid concentration of radio-iodine is evident in gastric mucosa of the stomach, in salivary glands, oral mucosa and in the periencephalic and cerebrospinal fluid (left). In the thyroid gland, I-concentration is more progressive, also in the reservoir (from 1% after 30 minutes, to 5.8 % after 48 hours, of the total injected dose.
Gastric cancer shows a male predominance in its incidence as up to two males are affected for every female. Estrogen may protect women against the development of this cancer form.
Approximately 10% of cases show a genetic component.
People may possess certain risk factors, such as those that are physical or genetic, that can alter their susceptibility for gastric cancer. Obesity is one such physical risk factor that has been found to increase the risk of gastric adenocarcinoma by contributing to the development of gastroesphageal reflux disease (GERD).The exact mechanism by which obesity causes GERD is not completely known. Studies hypothesize that increased dietary fat leading to increased pressure on the stomach and the lower esophageal sphincter, due to excess adipose tissue, could play a role, yet no statistically significant data has been collected. However, the risk of gastric cardia adenocarcinoma, with GERD present, has been found to increase more than 2 times for an obese person. A genetic risk factor for gastric cancer is a genetic defect of the CDH1 gene known as hereditary diffuse gastric cancer (HDGC). The CDH1 gene, which codes for E-cadherin, lies on the 16th chromosome.When the gene experiences a particular mutation, gastric cancer develops through a mechanism that is not fully understood.This mutation is considered autosomal dominant meaning that half of a carrier’s children will likely experience the same mutation.Diagnosis of hereditary diffuse gastric cancer usually takes place when at least two cases involving a family member, such as a parent or grandparent, are diagnosed, with at least one diagnosed before the age of 50.The diagnosis can also be made if there are at least three cases in the family, in which case age is not considered.
Computed tomography or CT scanning of the abdomen may reveal gastric cancer, but is more useful to determine invasion into adjacent tissues, or the presence of spread to local lymph nodes. Wall thickening of more than 1 cm that is focal, eccentric and enhancing favours malignancy.
In 2013, Chinese and Israeli scientists reported a successful pilot study of a breathalyzer-style breath test intended to diagnose stomach cancer by analyzing exhaled chemicals without the need for an intrusive endoscopy. A larger-scale clinical trial is now underway.
Abnormal tissue seen in a gastroscope examination will be biopsied by the surgeon or gastroenterologist. This tissue is then sent to a pathologist for histological examination under a microscope to check for the presence of cancerous cells. A biopsy, with subsequent histological analysis, is the only sure way to confirm the presence of cancer cells.
Various gastroscopic modalities have been developed to increase yield of detected mucosa with a dye that accentuates the cell structure and can identify areas of dysplasia. Endocytoscopy involves ultra-high magnification to visualise cellular structure to better determine areas of dysplasia. Other gastroscopic modalities such as optical coherence tomography are also being tested investigationally for similar applications.
Gastric adenocarcinoma is a malignant epithelial tumour, originating from glandular epithelium of the gastric mucosa. Stomach cancers are overwhelmingly adenocarcinomas (90%). Histologically, there are two major types of gastric adenocarcinoma (Lauren classification): intestinal type or diffuse type. Adenocarcinomas tend to aggressively invade the gastric wall, infiltrating the muscularis mucosae, the submucosa and thence the muscularis propria. Intestinal type adenocarcinoma tumour cells describe irregular tubular structures, harbouring pluristratification, multiple lumens, reduced stroma ("back to back" aspect). Often, it associates intestinal metaplasia in neighbouring mucosa. Depending on glandular architecture, cellular pleomorphism and mucosecretion, adenocarcinoma may present 3 degrees of differentiation: well, moderate and poorly differentiated. Diffuse type adenocarcinoma (mucinous, colloid, linitis plastica, leather-bottle stomach) tumour cells are discohesive and secrete mucus, which is delivered in the interstitium, producing large pools of mucus/colloid (optically "empty" spaces). It is poorly differentiated. If the mucus remains inside the tumour cell, it pushes the nucleus to the periphery: "signet-ring cell".
If cancer cells are found in the tissue sample, the next step is to stage, or find out the extent of the disease. Various tests determine whether the cancer has spread and, if so, what parts of the body are affected. Because stomach cancer can spread to the liver, the pancreas, and other organs near the stomach as well as to the lungs, the doctor may order a CT scan, a PET scan, an endoscopic ultrasound exam, or other tests to check these areas. Blood tests for tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) may be ordered, as their levels correlate to extent of metastasis, especially to the liver, and the cure rate.
Staging may not be complete until after surgery. The surgeon removes nearby lymph nodes and possibly samples of tissue from other areas in the abdomen for examination by a pathologist.
The clinical stages of stomach cancer are:
Stage 0. Limited to the inner lining of the stomach. Treatable by endoscopic mucosal resection when found very early (in routine screenings); otherwise by gastrectomy and lymphadenectomy without need for chemotherapy or radiation.
Stage I. Penetration to the second or third layers of the stomach (Stage 1A) or to the second layer and nearby lymph nodes(Stage 1B). Stage 1A is treated by surgery, including removal of the omentum. Stage 1B may be treated with chemotherapy (5-fluorouracil) and radiation therapy.
Stage II. Penetration to the second layer and more distant lymph nodes, or the third layer and only nearby lymph nodes, or all four layers but not the lymph nodes. Treated as for Stage I, sometimes with additional neoadjuvant chemotherapy.
Stage III. Penetration to the third layer and more distant lymph nodes, or penetration to the fourth layer and either nearby tissues or nearby or more distant lymph nodes. Treated as for Stage II; a cure is still possible in some cases.
Stage IV. Cancer has spread to nearby tissues and more distant lymph nodes, or has metastatized to other organs. A cure is very rarely possible at this stage. Some other techniques to prolong life or improve symptoms are used, including laser treatment, surgery, and/or stents to keep the digestive tract open, and chemotherapy by drugs such as 5-fluorouracil, cisplatin, epirubicin, etoposide, docetaxel, oxaliplatin, capecitabine or irinotecan.
In a study of open-access endoscopy in Scotland, patients were diagnosed 7% in Stage I 17% in Stage II, and 28% in Stage III. A Minnesota population was diagnosed 10% in Stage I, 13% in Stage II, and 18% in Stage III. However in a high-risk population in the Valdivia Province of southern Chile, only 5% of patients were diagnosed in the first two stages and 10% in stage III.
Getting rid of H. pylori in those who are infected decreases the risk of stomach cancer, at least in those who are Asian. Low doses of vitamins, especially from a healthy diet, decrease the risk of stomach cancer. A previous review of supplementation did not find supporting evidence and possibly worse outcomes.
Cancer of the stomach is difficult to cure unless it is found at an early stage (before it has begun to spread). Unfortunately, because early stomach cancer causes few symptoms, the disease is usually advanced when the diagnosis is made. Treatment for stomach cancer may include surgery,chemotherapy, and/or radiation therapy. New treatment approaches such as biological therapy and improved ways of using current methods are being studied in clinical trials.
Anatomy before Roux-en-y surgery to resect stomach cancer.
Surgery remains the only curative therapy for stomach cancer. Of the different surgical techniques, endoscopic mucosal resection (EMR) is a treatment for early gastric cancer (tumor only involves the mucosa) that has been pioneered in Japan, but is also available in the United States at some centers. In this procedure, the tumor, together with the inner lining of stomach (mucosa), is removed from the wall of the stomach using an electrical wire loop through the endoscope. The advantage is that it is a much smaller operation than removing the stomach.Endoscopic submucosal dissection (ESD) is a similar technique pioneered in Japan, used to resect a large area of mucosa in one piece. If the pathologic examination of the resected specimen shows incomplete resection or deep invasion by tumor, the patient would need a formal stomach resection.
Those with metastatic disease at the time of presentation may receive palliative surgery and while it remains controversial, due to the possibility of complications from the surgery itself and the fact that it may delay chemotherapy the data so far is mostly positive, with improved survival rates being seen in those treated with this approach.
The use of chemotherapy to treat stomach cancer has no firmly established standard of care. Unfortunately, stomach cancer has not been particularly sensitive to these drugs, and chemotherapy, if used, has usually served to palliatively reduce the size of the tumor, relieve symptoms of the disease and increase survival time. Some drugs used in stomach cancer treatment have included: 5-FU (fluorouracil) or its analog capecitabine, BCNU (carmustine), methyl-CCNU (semustine) and doxorubicin (Adriamycin), as well as mitomycin C, and more recently cisplatin and taxotere, often using drugs in various combinations. The relative benefits of these different drugs, alone and in combination, are unclear. Clinical researchers have explored the benefits of giving chemotherapy before surgery to shrink the tumor, or as adjuvant therapy after surgery to destroy remaining cancer cells. Recently, a targeted treatment called trastuzumab has become available for use with chemotherapy for the treatment of those overexpressing the HER2 gene in their tumor cells.
Radiation therapy (also called radiotherapy) may also be used to treat stomach cancer, often as an adjuvant to chemotherapy and/or surgery.
The prognosis of stomach cancer is generally poor, due to the fact the tumour has often metastasised by the time of discovery and the fact that most people with the condition are elderly (median age is between 70 and 75 years) at presentation. The 5-year survival rate for stomach cancer is reported to be less than 10%.
Stomach cancer is the fourth most common cancer worldwide with 930,000 cases diagnosed in 2002. It is more common in men and in developing countries. In 2012, it represented 8.5% of cancer cases in men, making it the fourth most common cancer in men. In 2012 number of deaths were 700,000 having decreased slightly from 774,000 in 1990 making it the third leading cause of cancer death after lung cancer and liver cancer.
Less than 5% of stomach cancers occur in people under 40 years of age with 81.1% of that 5% in the age-group of 30 to 39 and 18.9% in the age-group of 20 to 29.
In 2011, stomach cancer accounted for 0.64% of deaths (13,230 cases) in the United States. In China, stomach cancer accounted for 3.99% of all deaths (354,829 cases). The mortality rate was highest in the Maldives, stomach cancer accounting for 8.92% of all deaths.
Stomach cancer is the fifteenth most common cancer in the UK (around 7,100 people were diagnosed with stomach cancer in 2011), and it is the tenth most common cause of cancer death (around 4,800 people died in 2012).
Incidence and mortality rates of gastric cancer vary greatly in Africa. The GLOBOCAN system is currently the most widely used method to compare these rates between countries, but African incidence and mortality rates are seen to differ among countries possibly due to the lack of universal access to a registry system for all countries. Variation as drastic as estimated rates from 0.3/100000 in Mali to 20.3/100000 in Botswana have been observed. In Uganda, the incidence of gastric cancer has increased from the 1960s measurement of 0.8/100000 to 5.6/100000. Gastric cancer, though present, is relatively low when compared to countries with high incidence like Japan or China. One suspected cause of the variation within Africa and between other countries is due to different strains of the Helicobacter pylori bacteria. The trend commonly seen is that H. pylori infection increases the risk for gastric cancer, however this is not the case in Africa giving this phenomenon the name the “African enigma.” Although this bacteria is found in Africa, evidence has supported that different strains with mutations in the bacterial genotype may contribute to the difference in cancer development between African countries and others outside of the continent. But, increasing access to health care and treatment measures have been commonly associated with the rising incidence, particularly in Uganda. 
The stomach is a muscular organ of the gastrointestinal tract that holds food and begins the digestive process by secreting gastric juice. The most common cancers of the stomach are adenocarcinomas but other histological types have been reported. Signs vary but may include vomiting (especially if blood is present), weight loss, anemia, and lack of appetite. Bowel movements may be dark and tarry in nature. In order to determine whether cancer is present in the stomach, special X-rays and/or abdominal ultrasound may be performed. Gastroscopy, a test using an instrument called endoscope to examine the stomach, is a useful diagnostic tool that can also take samples of the suspected mass for histopathological analysis to confirm or rule out cancer. The most definitive method of cancer diagnosis is through open surgical biopsy. Most stomach tumors are malignant with evidence of spread to lymph nodes or liver, making treatment difficult. Except for lymphoma, surgery is the most frequent treatment option for stomach cancers but it is associated with significant risks.
^ abcdThrumurthy SG, Chaudry MA, Hochhauser D, Ferrier K, Mughal M; Chaudry; Hochhauser; Mughal (2013). "The diagnosis and management of gastric cancer". British Medical Journal347 (16): 1695–6. doi:10.1136/bmj.f6367. PMID24291271.
^Buckland G, Agudo A, Lujan L, Jakszyn P, Bueno-De-Mesquita HB, Palli D, Boeing H, Carneiro F, Krogh V; Agudo; Luján; Jakszyn; Bueno-De-Mesquita; Palli; Boeing; Carneiro; Krogh; Sacerdote; Tumino; Panico; Nesi; Manjer; Regnér; Johansson; Stenling; Sanchez; Dorronsoro; Barricarte; Navarro; Quirós; Allen; Key; Bingham; Kaaks; Overvad; Jensen; Olsen et al. (2009). "Adherence to a Mediterranean diet and risk of gastric adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study". American Journal of Clinical Nutrition91 (2): 381–90. doi:10.3945/ajcn.2009.28209. PMID20007304.
^Josefssson, M.; Ekblad, E. (2009). "22. Sodium Iodide Symporter (NIS) in Gastric Mucosa: Gastric Iodide Secretion". In Preedy, Victor R.; Burrow, Gerard N.; Watson, Ronald. Comprehensive Handbook of Iodine: Nutritional, Biochemical, Pathological and Therapeutic Aspects. Elsevier. pp. 215–220. ISBN978-0-12-374135-6.
^Venturi, S.; Donati, F.M.; Venturi, A.; Venturi, M. (2000). "Environmental Iodine Deficiency: A Challenge to the Evolution of Terrestrial Life?". Thyroid10 (8): 727–9. doi:10.1089/10507250050137851. PMID11014322.
^ abCrew K, Neugut A (January 2006). "Epidemiology of gastric cancer". World Journal of Gastroenterology12 (3): 354–62.
^Hampel Howard, Abraham Neena S., and El-Serag Hashem B. (August 2005). "Meta-Analysis: obesity and the risk for gastroesophageal reflux disease and its complications". Annal of Internal Medicine143 (3): 199–211.
^Inoue H, Kudo S-, Shiokawa A; Kudo; Shiokawa (2005). "Technology Insight: laser-scanning confocal microscopy and endocytoscopy for cellular observation of the gastrointestinal tract". Nature Clinical Practice Gastroenterology & Hepatology2 (1): 31–7. doi:10.1038/ncpgasthep0072. PMID16265098.
^Pentenero M, Carrozzo M, Pagano M, Gandolfo S; Carrozzo; Pagano; Gandolfo (2004). "Oral acanthosis nigricans, tripe palms and sign of leser-trelat in a patient with gastric adenocarcinoma". International Journal of Dermatology43 (7): 530–2. doi:10.1111/j.1365-4632.2004.02159.x. PMID15230897.
^Kumar; et al. (2010). Pathologic Basis of Disease (8th ed.). Saunders Elsevier. p. 784. ISBN978-1-4160-3121-5.
^Lim JS, Yun MJ, Kim MJ, Hyung WJ, Park MS, Choi JY, Kim TS, Lee JD, Noh SH, Kim KW; Yun; Kim; Hyung; Park; Choi; Kim; Lee; Noh; Kim (2006). "CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy". Radiographics26 (1): 143–156. doi:10.1148/rg.261055078. PMID16418249.
^Paterson HM, McCole D, Auld CD; McCole; Auld (2006). "Impact of open-access endoscopy on detection of early oesophageal and gastric cancer 1994–2003: population-based study". Endoscopy38 (5): 503–7. doi:10.1055/s-2006-925124. PMID16767587.
^Kong, P; Cai, Q; Geng, Q; Wang, J; Lan, Y; Zhan, Y; Xu, D (2014). "Vitamin intake reduce the risk of gastric cancer: meta-analysis and systematic review of randomized and observational studies.". PloS one9 (12): e116060. doi:10.1371/journal.pone.0116060. PMID25549091.
^Bjelakovic, G; Nikolova, D; Simonetti, RG; Gluud, C (16 July 2008). "Antioxidant supplements for preventing gastrointestinal cancers.". The Cochrane database of systematic reviews (3): CD004183. PMID18677777.
^Bjelakovic, G; Nikolova, D; Gluud, LL; Simonetti, RG; Gluud, C (14 March 2012). "Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.". The Cochrane database of systematic reviews3: CD007176. PMID22419320.
^Roopma Wadhwa, Takashi Taketa, Kazuki Sudo, Mariela A. Blum, Jaffer A. Ajani; Taketa; Sudo; Blum; Ajani (2013). "Modern Oncological Approaches to Gastric Adenocarcinoma". Gastroenterology Clinics of North America42 (2): 359–369. doi:10.1016/j.gtc.2013.01.011. PMID23639645.
^Jennifer L. Pretz, Jennifer Y. Wo, Harvey J. Mamon, Lisa A. Kachnic, Theodore S. Hong; Wo; Mamon; Kachnic; Hong (2011). "Chemoradiation Therapy: Localized Esophageal, Gastric, and Pancreatic Cancer". Surgical oncology clinics of North America22 (3): 511–524. doi:10.1016/j.soc.2013.02.005. PMID23622077.
^Scartozzi M, Galizia E, Verdecchia L, Berardi R, Antognoli S, Chiorrini S, Cascinu S; Galizia; Verdecchia; Berardi; Antognoli; Chiorrini; Cascinu (2007). "Chemotherapy for advanced gastric cancer: across the years for a standard of care". Expert Opinion on Pharmacotherapy8 (6): 797–808. doi:10.1517/14656522.214.171.1247. PMID17425475.
^Cabebe, EC; Mehta, VK; Fisher, G, Jr (21 January 2014). Talavera, F; Movsas, M; McKenna, R; Harris, JE, ed. "Gastric Cancer". Medscape Reference. WebMD. Retrieved 4 April 2014.
^World Cancer Report 2014. International Agency for Research on Cancer, World Health Organization. 2014. ISBN978-92-832-0432-9.
^Lozano, R; Naghavi, M; Foreman, K; Lim, S; Shibuya, K; Aboyans, V; Abraham, J; Adair, T; Aggarwal, R; Ahn, SY; Alvarado, M; Anderson, HR; Anderson, LM; Andrews, KG; Atkinson, C; Baddour, LM; Barker-Collo, S; Bartels, DH; Bell, ML; Benjamin, EJ; Bennett, D; Bhalla, K; Bikbov, B; Bin Abdulhak, A; Birbeck, G; Blyth, F; Bolliger, I; Boufous, S; Bucello, C et al. (15 December 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet380 (9859): 2095–128. doi:10.1016/S0140-6736(12)61728-0. PMID23245604.
^ abcdAsombang Akwi W, Rahman Rubayat, Ibdah Jamal A (2014). "Gastric cancer in Africa: Current management and outcomes". World Journal of Gastroenterology20: 3875–79. doi:10.3748/wjg.v20.i14.3875.
^ abLouw J. A., Kidd M. S. G., Kummer A. F., Taylor K., Kotze U., and Hanslo D. (November 2001). "The relationship between helicobacter pylori infection, the virulence genotypes of the infecting strain and gastric cancer in the African setting". Helicobacter6 (4): 268–73.